Eurofins Launches New Multiplex RT-PCR Respiratory Panel for SARS-CoV-2, Flu A/B, and RSV A/B

Eurofins Technologies (Luxembourg) has launched two RT-PCR assays to accurately diagnose respiratory diseases caused by SARS-CoV-2, Influenza virus or RSV. Since initial symptoms produced by these pathogens are indistinguishable, access to accurate and reliable tests will help clinicians improve patient care.

These new CE-marked multiplex kits have been specifically designed to detect and differentiate three viral infections in the same PCR run. The Mplex SARS-CoV-2+, Flu A, Flu B (C1) RT-PCR assay facilitates differentiation, in a single reaction, between Influenza A, B, and SARS-CoV-2, with simultaneous detection of two SARS-CoV-2 targets (N-gene + RdRP gene) as recommended by the WHO. The RSV A, RSV B RT-PCR assay can differentiate between respiratory syncytial virus A and B.

Both kits can be processed in parallel on the same plate, using the same temperature profile, and provide results in approximately one hour. An internal control (RNaseP) is included for adequate sample processing, and to monitor RNA extraction and the presence of potential inhibitors in the RT-PCR reaction. The AriaDx and AriaMx thermocyclers from Agilent Technologies are validated for both assays. ABI Prism 7500 Fast SDS and QuantStudio 5 from Applied Biosystems, CFX96 Touch from Bio-Rad, and LightCycler 480 II from Roche are validated for the RSV A, RSV B RT-PCR kit.

Related Links:
Eurofins Technologies